1887

oa Southern African Journal of Epidemiology and Infection - A comparative in vitro microbiological evaluation of generic meropenem compounds against the innovator compound : original research

 

Abstract

: Meropenem is a broad-spectrum carbapenem widely used in the treatment of critically ill patients. A generic meropenem product has recently become available in South Africa and we aimed to compare the generic product with the innovator product using established in vitro microbiological testing methods.


: Comparative minimum inhibitory concentrations (MICs) were determined for 115 clinically relevant isolates using the broth microdilution reference method. Comparative analysis of MIC was done using categorical and essential agreement. A subset of isolates was evaluated using minimum bactericidal concentration (MBC) testing.
: The overall essential agreement exceeded the international standard of > 90%. A single major error and six minor errors were detected in 230 comparative MICs. For the 55 tested, the MIC and MIC were 0.03 μg/ml and 0.06 μg/ml respectively, with no difference between extended-spectrum β-lactamase producers (ESBL) and non-ESBL isolates. Bactericidal activity was demonstrated for both generic and innovator products in all isolates tested. For eight of the 11 isolates, the MBC was only twice the MIC.
: Reference method MIC and MBC testing of a large sample of clinically relevant microorganisms against meropenem has demonstrated comparable in vitro activity between the innovator and generic products. Low MICs and bactericidal activity at concentrations close to the MIC indicate that meropenem remains a useful agent in the treatment of infections caused by ESBL-producing .

Loading

Article metrics loading...

/content/mp_sajei/26/2/EJC80906
2011-01-01
2016-12-03
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error